144 related articles for article (PubMed ID: 16459340)
21. Prophylactic heparin in palliative care: a cautious welcome..
Pace V; Hall E; Bailey C
BMJ; 2006 Mar; 332(7543):728-9. PubMed ID: 16565137
[No Abstract] [Full Text] [Related]
22. A prospective observational study of a cohort of outpatients with an acute medical event and reduced mobility: incidence of symptomatic thromboembolism and description of thromboprophylaxis practices.
Bosson JL; Pouchain D; Bergmann JF;
J Intern Med; 2006 Aug; 260(2):168-76. PubMed ID: 16882282
[TBL] [Abstract][Full Text] [Related]
23. Management of venous thromboembolism in the palliative care setting.
Noble S
Int J Palliat Nurs; 2007 Dec; 13(12):574-9. PubMed ID: 18399382
[TBL] [Abstract][Full Text] [Related]
24. Controversial issues in thromboprophylaxis with low-molecular weight heparins in palliative care.
Tassinari D; Santelmo C; Scarpi E; Tombesi P; Sartori S
J Pain Symptom Manage; 2008 Aug; 36(2):e3-4. PubMed ID: 18655952
[No Abstract] [Full Text] [Related]
25. Venous thromboembolism in patients with advanced cancer under palliative care: additional risk factors, primary/secondary prophylaxis and complications observed under normal clinical practice.
Soto-Cárdenas MJ; Pelayo-García G; Rodríguez-Camacho A; Segura-Fernández E; Mogollo-Galván A; Giron-Gonzalez JA
Palliat Med; 2008 Dec; 22(8):965-8. PubMed ID: 18952751
[TBL] [Abstract][Full Text] [Related]
26. Low molecular weight heparin for the prevention and treatment of venous thromboembolism.
Raskob GE
Curr Opin Pulm Med; 1996 Jul; 2(4):305-10. PubMed ID: 9363157
[TBL] [Abstract][Full Text] [Related]
27. A review of the practical advantages of low molecular weight heparin in the treatment of cancer-related venous thromboembolism.
Rhodes S; Bond S
Eur J Oncol Nurs; 2008 Dec; 12(5):425-9. PubMed ID: 18842458
[TBL] [Abstract][Full Text] [Related]
28. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism.
Lee AY; Rickles FR; Julian JA; Gent M; Baker RI; Bowden C; Kakkar AK; Prins M; Levine MN
J Clin Oncol; 2005 Apr; 23(10):2123-9. PubMed ID: 15699480
[TBL] [Abstract][Full Text] [Related]
29. Low-molecular-weight heparin in cancer-associated thrombosis: treatment, secondary prevention, and survival.
Nishioka J; Goodin S
J Oncol Pharm Pract; 2007 Jun; 13(2):85-97. PubMed ID: 17873108
[TBL] [Abstract][Full Text] [Related]
30. Use of venous thromboembolism prophylaxis for surgical patients: a multicentre analysis of practice in Spain.
Otero R; Uresandi F; Cayuela A; Blanquer J; Cabezudo MA; De Gregorio MA; Lobo JL; Nauffal D; Oribe M
Eur J Surg; 2001 Mar; 167(3):163-7. PubMed ID: 11316398
[TBL] [Abstract][Full Text] [Related]
31. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis.
Breddin HK; Hach-Wunderle V; Nakov R; Kakkar VV;
N Engl J Med; 2001 Mar; 344(9):626-31. PubMed ID: 11228276
[TBL] [Abstract][Full Text] [Related]
32. Cost effectiveness of thromboprophylaxis with a low-molecular-weight heparin versus unfractionated heparin in acutely ill medical inpatients.
McGarry LJ; Thompson D; Weinstein MC; Goldhaber SZ
Am J Manag Care; 2004 Sep; 10(9):632-42. PubMed ID: 15515996
[TBL] [Abstract][Full Text] [Related]
33. Heparin and low-molecular-weight heparin therapy for venous thromboembolism. The twilight of anticoagulant monitoring.
Hull RD; Pineo GF; Stein P
Int Angiol; 1998 Dec; 17(4):213-24. PubMed ID: 10204652
[TBL] [Abstract][Full Text] [Related]
34. Low-molecular-weight heparin for thromboprophylaxis.
Camporese G; Bernardi E
Curr Opin Pulm Med; 2009 Sep; 15(5):443-54. PubMed ID: 19593139
[TBL] [Abstract][Full Text] [Related]
35. Preventing postsurgical venous thromboembolism: pharmacological approaches.
Tufano A; Coppola A; Cerbone AM; Ruosi C; Franchini M
Semin Thromb Hemost; 2011 Apr; 37(3):252-66. PubMed ID: 21455859
[TBL] [Abstract][Full Text] [Related]
36. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
Koopman MM; Prandoni P; Piovella F; Ockelford PA; Brandjes DP; van der Meer J; Gallus AS; Simonneau G; Chesterman CH; Prins MH
N Engl J Med; 1996 Mar; 334(11):682-7. PubMed ID: 8594426
[TBL] [Abstract][Full Text] [Related]
37. Barriers to the diagnosis and treatment of venous thromboembolism in advanced cancer patients: a qualitative study.
Sheard L; Prout H; Dowding D; Noble S; Watt I; Maraveyas A; Johnson M
Palliat Med; 2013 Apr; 27(4):339-48. PubMed ID: 23093572
[TBL] [Abstract][Full Text] [Related]
38. Low-molecular-weight heparin in oncology.
Zacharski LR; Loynes JT
Anticancer Res; 2003; 23(3C):2789-93. PubMed ID: 12926114
[TBL] [Abstract][Full Text] [Related]
39. [Prevention of venous thromboembolism in internal medicine and neurology].
Malý J; Dulícek P; Penka M; Malý R; Gumulec J
Vnitr Lek; 2006 Mar; 52 Suppl 1():63-7. PubMed ID: 16637452
[TBL] [Abstract][Full Text] [Related]
40. Cancer-associated venous thrombosis in the surgical setting.
Behranwala KA; Williamson RC
Ann Surg; 2009 Mar; 249(3):366-75. PubMed ID: 19247020
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
